What is the role of S‑adenosyl‑methionine (SAMe) as an adjunct therapy in the treatment of alcoholic hepatitis?

SAMe Has No Established Role in Treating Alcohol-Associated Hepatitis

S-adenosyl-methionine (SAMe) is not recommended for the treatment of alcoholic hepatitis based on current evidence showing no survival benefit or improvement in liver function compared to placebo.

Evidence Summary

Guideline Recommendations

The major international guidelines for alcohol-associated liver disease do not recommend SAMe as a treatment option for alcoholic hepatitis:

• The 2022 French Association for the Study of the Liver guidelines 1 make no mention of SAMe in their treatment algorithm, focusing instead on corticosteroids as first-line therapy and N-acetylcysteine as a potential adjunct.

• The 2020 AASLD Practice Guidance 2 explicitly states that "older trials of various agents, including antioxidants like S-adenosylmethionine...have failed to demonstrate improvement in survival."

• The 2018 EASL Clinical Practice Guidelines 3 do not include SAMe in their treatment recommendations for alcohol-related liver disease.

• The 2013 Korean guidelines 4 discuss various antioxidants but do not recommend SAMe for alcoholic hepatitis treatment.

Clinical Trial Evidence

The highest quality evidence comes from a 2011 randomized, double-blind, placebo-controlled trial 5 that directly tested SAMe in 37 patients with alcoholic liver disease:

• Primary endpoints (liver enzymes and histopathology): No significant differences between SAMe (1.2 g/day) and placebo groups
• Liver function tests: Both groups improved equally, attributed to alcohol abstinence rather than SAMe
• Liver histopathology: No differences in steatosis, inflammation, fibrosis, or Mallory-Denk bodies between groups
• Conclusion: "24 weeks of therapy with SAM was no more effective than placebo in the treatment for ALD"

A 2006 Cochrane systematic review 6 analyzed 9 randomized trials (434 patients) and found:

• No significant effect on all-cause mortality (RR 0.62,95% CI 0.30-1.26)
• No significant effect on liver-related mortality (RR 0.68,95% CI 0.31-1.48)
• No significant effect on complications (RR 1.35,95% CI 0.84-2.16)
• Conclusion: "We could not find evidence supporting or refuting the use of SAMe for patients with alcoholic liver diseases"

Recent Exploratory Data

A 2025 systematic review 7 examining anti-inflammatory therapies noted that SAMe combined with corticosteroids showed some efficacy in 1- and 6-month survival in limited studies, but emphasized significant study heterogeneity and lack of high-quality RCTs. This does not change the current evidence-based recommendation against routine use.

Current Standard of Care

For severe alcoholic hepatitis (mDF ≥32), the evidence-based treatment is:

1. Prednisolone 40 mg/day for 28 days (first-line) 1, 2, 3
2. Consider adding N-acetylcysteine (not SAMe) to corticosteroids for potential short-term survival benefit 1
3. Assess response at day 7 using Lille score to identify non-responders 1, 3

Mechanistic Rationale vs. Clinical Reality

While SAMe theoretically addresses methionine metabolism disruption in ALD by:

• Serving as a methyl donor
• Supporting glutathione synthesis
• Reducing oxidative stress 8, 9, 10

This biological plausibility has not translated into clinical benefit when tested in rigorous trials 5, 6. The improvement seen in alcoholic liver disease patients is primarily driven by alcohol abstinence, not SAMe supplementation.

Clinical Bottom Line

Do not prescribe SAMe for alcoholic hepatitis. Focus instead on:

• Alcohol abstinence (most important intervention) 1, 2
• Nutritional support (35-40 kcal/kg/day, 1.2-1.5 g protein/kg/day) 4, 3
• Corticosteroids for severe disease without contraindications 1, 2, 3
• Addiction treatment for long-term outcomes 1

The evidence is clear: SAMe offers no mortality benefit, no improvement in liver function beyond abstinence, and no role in current treatment algorithms for alcohol-associated hepatitis.